Pro Medicus Limited, a medical imaging software company listed on the ASX under the ticker $PME, reported strong financial results for the fiscal year 2024. The company achieved a revenue of $166 million, marking a 31% increase from the previous year. Revenue from customers also rose by 29% to $162 million. The gross profit was $166 million with a 100% margin, up by 25 basis points. Earnings before interest and taxes (EBIT) reached $116 million, reflecting a 35% increase with a 70% margin, up by 240 basis points. Net income stood at $83 million, a 37% increase, with a 50% margin, up by 215 basis points. Operating cash flow was $82 million, up by 31% with a 49% margin, and free cash flow was $75 million, up by 34%. The company's technological market advantage continues to be a significant factor in its performance, according to Portfolio Manager Tobias Yao. Pro Medicus is noted for its high valuation in the market.